Cargando…
Dexamethasone intravitreous implant vs bevacizumab for central retinal vein occlusion‐related macular oedema: A prospective randomized comparison—Comment
Autores principales: | Wen, Dejia, Li, Xiao‐Rong, He, Ye, Ren, Xinjun, Zheng, Chuanzhen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767533/ https://www.ncbi.nlm.nih.gov/pubmed/30801910 http://dx.doi.org/10.1111/ceo.13483 |
Ejemplares similares
-
Intravitreal dexamethasone implant versus triamcinolone acetonide for macular oedema of central retinal vein occlusion: quantifying efficacy and safety
por: Mishra, S. K., et al.
Publicado: (2018) -
Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion
por: Hikichi, Taiichi, et al.
Publicado: (2014) -
Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema
por: Laine, Ilkka, et al.
Publicado: (2017) -
Dexamethasone Intravitreal Implant Rescue Treatment for Bevacizumab Refractory Macular Edema Secondary to Branch Retinal Vein Occlusion
por: Lee, Kyou Ho, et al.
Publicado: (2017) -
Intravitreal dexamethasone implant for central retinal vein occlusion without macular edema
por: Choi, Eun Young, et al.
Publicado: (2019)